Recombinant versus urinary gonadotropins for ovarian stimulation in infertile women undergoing intracytoplasmic sperm injection [ICSI] treatment

ABSTRACT

This study included 64 women underwent controlled ovarian hyper stimulation and ICSI. Patients were prospectively randomized to receive either urinary hMG or r-FSH for controlled ovarian hyper stimulation after a long protocol of pituitary down-regulation was achieved in all patients by giving analogues on day 21 of the menstrual cycle. The main endpoint was ongoing pregnancy rate following one treatment cycle. Secondary outcomes included total dose and cost of gonadotropin used, cycle cancellation due to poor response, number and quality of oocytes collected, fertilization rate, embryos transferred and adverse effects; ovarian hyper stimulation syndrome, multiple pregnancy and abortion rates. The results revealed that there was insufficient evidence of significant statistical difference between hMG and FSH in clinical ongoing pregnancy rate. Furthermore, there was no difference on any of the secondary outcomes. However, the cost of a treatment cycle was 47% cheaper in hMG group than in FSH group